Alumis Reports Q1 Financials, Secures $324M from Public Offering, Launches $300M ATM, and Reviews Lonigutamab Program

summarizeSummary

Alumis Inc. reported Q1 2026 financials with a reduced net loss but increased cash burn. The company significantly boosted its cash position with a $324.4 million public offering and established a new $300 million ATM program. However, it announced a strategic review for the lonigutamab program, indicating a potential setback for the acquired asset.

check_boxKey Events

• Q1 2026 Financial Results

  Reported a net loss of $93.1 million for Q1 2026, an improvement from $99.0 million in Q1 2025. Cash used in operating activities increased to $87.1 million from $80.4 million year-over-year.

• Successful Public Offering

  Completed a public offering in January 2026, raising $324.4 million in net proceeds from the sale of 20,297,500 shares at $17.00 per share. This significantly strengthened the company's cash position to $569.5 million, providing a runway of at least 12 months.

• New At-The-Market (ATM) Program

  Established a new ATM equity offering program in March 2026, allowing the company to sell up to $300.0 million in common stock from time to time. No shares have been sold under this program as of March 31, 2026.

• Strategic Review of Lonigutamab Program

  Decided to explore strategic alternatives for the lonigutamab program, an asset acquired in the May 2025 ACELYRIN merger (which included $51.0 million in intangible assets). This indicates a potential impairment or divestiture.

auto_awesomeAnalysis

Alumis Inc. reported its first quarter 2026 financial results, showing a reduced net loss of $93.1 million compared to $99.0 million in Q1 2025. However, cash used in operating activities increased to $87.1 million from $80.4 million in the prior year. The company significantly bolstered its liquidity with a public offering in January 2026, raising $324.4 million in net proceeds by selling 20,297,500 shares at $17.00 per share. This was followed by the establishment of a new $300 million At-The-Market (ATM) equity offering program in March 2026, providing additional capital-raising flexibility, though no shares have been sold under this program yet. A notable negative development is the decision to explore strategic alternatives for the lonigutamab program, an asset acquired in the May 2025 ACELYRIN merger, which had an intangible asset value of $51.0 million. This suggests a potential impairment or divestiture of a previously acquired asset. The company maintains a cash runway of at least 12 months and plans to submit an NDA for its lead candidate, envu, in the second half of 2026, with Phase 2 SLE trial results expected in Q3 2026.